Detect altered DNA
With over 90% sensitivity and specificity at detecting BE and EAC, the EsoGuard esophageal DNA test allows detection of these conditions in a simple office-based procedure WITHOUT endoscopy.
1
408
patient human study
published in
Science Translational Medicine
1
>90%
sensitivity & specificity
at detecting BE, with and without dysplasia, as
well as esophageal adenocarcinoma
1
EsoGuard analyzes methylation at
31 sites on 2 genes
1
A test that goes down easy
Barrett’s esophagus is a premalignant condition of the distal esophagus that increases the risk of esophageal cancer. Unfortunately, screening for Barrett’s esophagus currently requires endoscopy, an invasive and expensive procedure, and thus, it is not routinely performed. Moinova et al. have now demonstrated a simplified approach to screening by identifying a pair of DNA methylation markers that correlate with the presence of Barrett’s esophagus. The authors also invented a swallowable balloon-based device that can capture DNA samples for methylation analysis and found that it is well tolerated in patients and provides >90% sensitivity and specificity compared to endoscopy, suggesting its potential as a screening method.
Science Translational Medicine 17 Jan 2018:
Vol. 10, Issue 424, eaao5848
DOI: 10.1126/scitranslmed.aao5848
How it works
Distal esophageal cells are sampled in a simple office-based procedure, shipped in preservative with the provided mailer, and processed at our laboratory. Results are typically available within 3 weeks.
01
Cell Collection
Distal esophageal cells are sampled in a simple office-based procedure and sent to our laboratory.
02
Test
The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.
03
Results
The physician receives a report with a positive or negative result indicating whether or not epigenetic changes consistent with BE/EAC were detected.
What's in the kit
Meet the team behind the test
Researchers, Physicians, Scientists, Innovators, Educators
EsoGuard arose out a collaboration among faculty at Case Western Reserve University, including a renowned cancer geneticist, a passionate gastroenterologist and a dedicated pathologist.
SANDY MARKOWITZ, MD
Case Western Reserve University
University Hospitals Cleveland Medical Center
AMITABH CHAK, MD
Case Western Reserve University
University Hospitals Cleveland Medical Center
JOE WILLIS, MD
Case Western Reserve University
University Hospitals Cleveland Medical Center
Ready to start screening with EsoGuard?
Incorporating EsoGuard in your practice is easy. Reach out today and we'll get you started.
REFERENCES:
1. Science Translational Medicine 17 Jan 2018: Vol. 10, Issue 424, eaao5848, DOI: 10.1126/scitranslmed.aao5848